Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (39) 39
male (34) 34
female (32) 32
index medicus (31) 31
middle aged (30) 30
adult (28) 28
hematology (26) 26
aged (24) 24
oncology (20) 20
prognosis (15) 15
adolescent (12) 12
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
chemotherapy (12) 12
survival (11) 11
treatment outcome (11) 11
kaplan-meier estimate (10) 10
disease-free survival (9) 9
young adult (9) 9
diagnosis (8) 8
risk factors (8) 8
aged, 80 and over (7) 7
cancer (7) 7
minimal residual disease (7) 7
recurrence (7) 7
rituximab (7) 7
abridged index medicus (6) 6
care and treatment (6) 6
expression (6) 6
leukemia (6) 6
remission induction (6) 6
therapy (6) 6
vidarabine - analogs & derivatives (6) 6
analysis (5) 5
antineoplastic combined chemotherapy protocols - administration & dosage (5) 5
cyclophosphamide - administration & dosage (5) 5
hematology, oncology and palliative medicine (5) 5
leukemia, myeloid, acute - genetics (5) 5
mitoxantrone - administration & dosage (5) 5
stem cell transplantation (5) 5
stem-cell transplantation (5) 5
time factors (5) 5
transplantation (5) 5
vidarabine - administration & dosage (5) 5
apparatus for making beverages (4) 4
b-cell lymphoma (4) 4
bortezomib (4) 4
coffee mills (4) 4
combined modality therapy (4) 4
domestic articles or appliances (4) 4
furniture (4) 4
gene (4) 4
genes (4) 4
genetic aspects (4) 4
group-b (4) 4
human necessities (4) 4
kitchen equipment (4) 4
leukemia, lymphocytic, chronic, b-cell - drug therapy (4) 4
leukemia, myeloid, acute - mortality (4) 4
lymphoma (4) 4
multiple myeloma (4) 4
multiple myeloma - therapy (4) 4
multivariate analysis (4) 4
non-hodgkins-lymphoma (4) 4
proportional hazards models (4) 4
research (4) 4
retrospective studies (4) 4
spain (4) 4
spice mills (4) 4
stem cells (4) 4
suction cleaners in general (4) 4
survival analysis (4) 4
vidarabine - adverse effects (4) 4
acute lymphatic leukemia (3) 3
acute lymphocytic leukemia (3) 3
adults (3) 3
aml (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
burkitt lymphoma - drug therapy (3) 3
cohort studies (3) 3
competing risk (3) 3
consolidation (3) 3
cyclophosphamide - adverse effects (3) 3
cytogenetic analysis (3) 3
dexamethasone (3) 3
drug administration schedule (3) 3
feasibility studies (3) 3
follicular lymphoma (3) 3
follow-up studies (3) 3
genetics & heredity (3) 3
hematopoietic stem cell transplantation (3) 3
hiv infection (3) 3
immunohistochemistry (3) 3
leucèmia mieloide (3) 3
lymphocytes b (3) 3
medical research (3) 3
medicine, experimental (3) 3
micro rnas (3) 3
micrornas (3) 3
mitoxantrone - adverse effects (3) 3
mutation (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival
by Juan José Lahuerta and Maria Victoria Mateos and Joaquin Martínez-López and Laura Rosiñol and Anna Sureda and Javier de la Rubia and José García-Laraña and Rafael Martínez-Martínez and Miguel T. Hernández-García and Dolores Carrera and Joan Besalduch and Felipe de Arriba and José María Ribera and Lourdes Escoda and Belén Hernández-Ruiz and Javier García-Frade and Concepción Rivas-González and Adrían Alegre and Joan Bladé and Jesús F. San Miguel
Journal of Clinical Oncology, ISSN 0732-183X, 12/2008, Volume 26, Issue 35, pp. 5775 - 5782
Purpose Complete response (CR) is considered an important goal in most hematologic malignancies. However, in multiple myeloma (MM), there is no consensus... 
INTENSIVE TREATMENT | COMPLETE REMISSION | INDUCTION CHEMOTHERAPY | ONCOLOGY | BONE-MARROW-TRANSPLANTATION | STEM-CELL-TRANSPLANTATION | AUTOLOGOUS TRANSPLANTATION | RANDOMIZED-TRIAL | HIGH-DOSE MELPHALAN | PREVIOUSLY UNTREATED MYELOMA | MINIMAL RESIDUAL DISEASE | Prospective Studies | Multiple Myeloma - mortality | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Transplantation, Autologous | Treatment Outcome | Remission Induction | Spain | Stem Cell Transplantation | Disease-Free Survival | Multiple Myeloma - therapy | Time Factors | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adult | Female | Aged | Transplantation Conditioning
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia
by Francesc Bosch and Pau Abrisqueta and Neus Villamor and María José Terol and Eva González-Barca and Christelle Ferra and Marcos González Diaz and Eugenia Abella and Julio Delgado and Félix Carbonell and José Antonio García Marco and Lourdes Escoda and Secundino Ferrer and Encarnación Monzó and Yolanda González and Cristina Estany and Isidro Jarque and Olga Salamero and Ana Muntañola and Emili Montserrat
Journal of Clinical Oncology, ISSN 0732-183X, 09/2009, Volume 27, Issue 27, pp. 4578 - 4584
Purpose The addition of monoclonal antibodies to chemotherapy has significantly improved treatment of chronic lymphocytic leukemia (CLL). Based on excellent... 
SURVIVAL | TRIAL | B-CELL LYMPHOMA | PLUS CYCLOPHOSPHAMIDE | ONCOLOGY | INITIAL THERAPY | GENOMIC ABERRATIONS | 1ST-LINE THERAPY | MINIMAL RESIDUAL DISEASE | CHLORAMBUCIL | PREVIOUSLY UNTREATED PATIENTS | Cyclophosphamide - administration & dosage | Antibodies, Monoclonal, Murine-Derived | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Mitoxantrone - administration & dosage | Humans | Middle Aged | Male | Vidarabine - analogs & derivatives | Antibodies, Monoclonal - administration & dosage | Adult | Female | Aged | Vidarabine - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication
by Francesc Bosch and Ana Ferrer and Neus Villamor and Marcos González and Javier Briones and Eva González-Barca and Eugenia Abella and Santiago Gardella and Lourdes Escoda and Elena Pérez-Ceballos and Antoni Asensi and Ma José Sayas and Llorenç Font and Albert Altés and Ana Muntañola and Paola Bertazzoni and María Rozman and Marta Aymerich and Eva Giné and Emili Montserrat
Clinical Cancer Research, ISSN 1078-0432, 01/2008, Volume 14, Issue 1, pp. 155 - 161
Purpose: Fludarabine, cyclophosphamide, and mitoxantrone (FCM) results in a high response rate in previously treated patients with chronic lymphocytic leukemia... 
ZAP-70 | FCM | genes | Phase I-III Clinical Trials | Chronic Lymphocytic leukemia | Minimal residual disease | IgV | Leukemias and lymphomas | Hematologic, other | PLUS CYCLOPHOSPHAMIDE | ONCOLOGY | RITUXIMAB | PHASE-II | GENOMIC ABERRATIONS | RANDOMIZED-TRIAL | STEM-CELL TRANSPLANTATION | 1ST-LINE THERAPY | COMBINATION | MINIMAL RESIDUAL DISEASE | B-VIRUS REACTIVATION | Neoplasm, Residual - pathology | Cyclophosphamide - administration & dosage | Neoplasm, Residual - metabolism | Mitoxantrone - administration & dosage | Humans | Middle Aged | ZAP-70 Protein-Tyrosine Kinase - biosynthesis | Male | Cyclophosphamide - adverse effects | Female | Mitoxantrone - adverse effects | Vidarabine - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Vidarabine - analogs & derivatives | Remission Induction | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | L-Lactate Dehydrogenase - blood | ADP-ribosyl Cyclase 1 - biosynthesis | Leukemia, Lymphocytic, Chronic, B-Cell - metabolism | Neoplasm, Residual - drug therapy | Survival Analysis | Immunoglobulin Variable Region - genetics | Vidarabine - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Immunoglobulin Heavy Chains - genetics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text The poor prognosis of low hypodiploidy in adults with B‐cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients
by Ribera, Jordi and Granada, Isabel and Morgades, Mireia and Vives, Susana and Genescà, Eulàlia and González, Celia and Nomdedeu, Josep and Escoda, Lourdes and Montesinos, Pau and Mercadal, Santiago and Coll, Rosa and González‐Campos, José and Abella, Eugenia and Barba, Pere and Bermúdez, Arancha and Gil, Cristina and Tormo, Mar and Pedreño, María and Martínez‐Carballeira, Daniel and Hernández‐Rivas, Jesús‐María and Orfao, Alberto and Martínez‐López, Joaquín and Esteve, Jordi and Bravo, Pilar and Garcia‐Guiñon, Antoni and Debén, Guillermo and Moraleda, José M and Queizán, José A and Ortín, Xavier and Moreno, María J and Feliu, Evarist and Solé, Francesc and Ribera, Josep M and PETHEMA Group, Spanish Society of Haematology and PETHEMA Grp and Spanish Soc Haematology and the PETHEMA Group, Spanish Society of Haematology
British Journal of Haematology, ISSN 0007-1048, 07/2019, Volume 186, Issue 2, pp. 263 - 268
The prognostic significance of low‐hypodiploidy has not been extensively evaluated in minimal residual disease (MRD)‐oriented protocols for adult acute... 
hypodiploidy | prognosis | acute lymphoblastic leukaemia | age | adults | IMPACT | HEMATOLOGY | CHILDREN | Aged patients | Prognosis | Elderly people | Acute lymphatic leukemia | Hypodiploidy | Leukemia | Minimal residual disease | Lymphocytes B | Precursors | Medical prognosis | Older people | Adults | Elderly | Geriatrics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Molecular profiling refines minimal residual disease‐based prognostic assessment in adults with Philadelphia chromosome‐negative B‐cell precursor acute lymphoblastic leukemia
by Ribera, Jordi and Zamora, Lurdes and Morgades, Mireia and Vives, Susana and Granada, Isabel and Montesinos, Pau and Gómez‐Seguí, Inés and Mercadal, Santiago and Guàrdia, Ramon and Nomdedeu, Josep and Pratcorona, Marta and Tormo, Mar and Martínez‐Lopez, Joaquín and Hernández‐Rivas, Jesús‐María and Ciudad, Juana and Orfao, Alberto and González‐Campos, José and Barba, Pere and Escoda, Lourdes and Esteve, Jordi and Genescà, Eulàlia and Solé, Francesc and Feliu, Evarist and Ribera, Josep‐Maria and Spanish Society of Hematology and Spanish PETHEMA Group and Spanish PETHEMA Grp and Spanish Soc Hematology and on behalf of the Spanish PETHEMA Group
Genes, Chromosomes and Cancer, ISSN 1045-2257, 11/2019, Volume 58, Issue 11, pp. 815 - 819
Minimal residual disease (MRD) assessment is an essential tool in contemporary acute lymphoblastic leukemia (ALL) protocols, being used for therapeutic... 
COPY NUMBER ALTERATIONS | ONCOLOGY | ADOLESCENTS | GENES | GENETICS & HEREDITY | RESISTANCE | ADVERSE | DELETIONS | Relapse | Transplantation | Genetic aspects | Adults | Acute lymphocytic leukemia | Hematopoietic stem cells | Diseases | Cancer | Profiling | Acute lymphatic leukemia | Leukemia | Health risks | Minimal residual disease | Stem cell transplantation | Lymphatic leukemia | Hemopoiesis | Philadelphia chromosome | Lymphocytes B | Risk assessment | Stem cells | Adolescents | Chromosomes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
by Gutiérrez-García, Gonzalo and Cardesa-Salzmann, Teresa and Climent, Fina and González-Barca, Eva and Mercadal, Santiago and Mate, José L and Sancho, Juan M and Arenillas, Leonor and Serrano, Sergi and Escoda, Lourdes and Martínez, Salomé and Valera, Alexandra and Martínez, Antonio and Jares, Pedro and Pinyol, Magdalena and García-Herrera, Adriana and Martínez-Trillos, Alejandra and Giné, Eva and Villamor, Neus and Campo, Elías and Colomo, Luis and López-Guillermo, Armando and Grp Estudi Limfomes Catalunya and Grup per l'Estudi dels Limfomes de Catalunya I Balears (GELCAB) and for the Grup per l'Estudi dels Limfomes de Catalunya I Balears (GELCAB)
Blood, ISSN 0006-4971, 05/2011, Volume 117, Issue 18, pp. 4836 - 4843
Diffuse large B-cell lymphomas (DLBCLs) can be divided into germinal-center B cell-like (GCB) and activated-B cell-like (ABC) subtypes by gene-expression... 
MOLECULAR SUBTYPES | SURVIVAL | MARKER | CHOP | RANDOMIZED CONTROLLED-TRIAL | TISSUE MICROARRAY | HEMATOLOGY | CHEMOTHERAPY PLUS RITUXIMAB | ELDERLY-PATIENTS | SUBSET | GERMINAL-CENTER | Immunohistochemistry | Prognosis | Oligonucleotide Array Sequence Analysis | Humans | Middle Aged | Kaplan-Meier Estimate | Rituximab | Immunophenotyping | Male | Antineoplastic Agents - therapeutic use | Gene Expression Profiling | Young Adult | Disease-Free Survival | Lymphoma, Large B-Cell, Diffuse - therapy | Algorithms | Immunotherapy | Adolescent | Aged, 80 and over | Lymphoma, Large B-Cell, Diffuse - immunology | Adult | Female | Aged | Lymphoma, Large B-Cell, Diffuse - genetics | Antibodies, Monoclonal, Murine-Derived - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Pomalidomide‐dexamethasone for treatment of soft‐tissue plasmacytomas in patients with relapsed / refractory multiple myeloma
by Jiménez‐Segura, Raquel and Granell, Miquel and Gironella, Mercè and Abella, Eugenia and García‐Guiñón, Antoni and Oriol, Albert and Cabezudo, Elena and Clapés, Victoria and Soler, Joan Alfons and Escoda, Lourdes and López-Pardo, Jordi and Fernández de Larrea, Carlos and Cibeira, Maria Teresa and Tovar, Natalia and Isola, Ignacio and Bladé, Joan and Rosiñol, Laura and GEMMAC and GEMMAC (Grup per l l'estudi del mieloma mútiple i l'amiloïdosi de Catalunya)
European Journal of Haematology, ISSN 0902-4441, 05/2019, Volume 102, Issue 5, pp. 389 - 394
Objective The presence of plasmacytomas (Ps) in patients with multiple myeloma (MM) is associated with a poor outcome, both in patients treated conventionally... 
plasmacytomas | multiple myeloma | pomalidomide | EFFICACY | EXTRAMEDULLARY DISEASE | THALIDOMIDE | BORTEZOMIB | INDUCTION | RELAPSE | IMPACT | THERAPY | HEMATOLOGY | PROGRESSION | REMISSION | Medical research | Care and treatment | Relapse | Dexamethasone | Multiple myeloma | Medicine, Experimental | Diseases | Steroids | Urine | Survival | Patients | Medical prognosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Copy number profiling of adult relapsed B‐cell precursor acute lymphoblastic leukemia reveals potential leukemia progression mechanisms
by Ribera, Jordi and Zamora, Lurdes and Morgades, Mireia and Mallo, Mar and Solanes, Neus and Batlle, Montserrat and Vives, Susana and Granada, Isabel and Juncà, Jordi and Malinverni, Roberto and Genescà, Eulàlia and Guàrdia, Ramon and Mercadal, Santiago and Escoda, Lourdes and Martinez‐Lopez, Joaquín and Tormo, Mar and Esteve, Jordi and Pratcorona, Marta and Martinez‐Losada, Carmen and Solé, Francesc and Feliu, Evarist and Ribera, Josep‐Maria and Spanish PETHEMA Grp Spanish Soc He and Spanish PETHEMA Group and the Spanish Society of Hematology and for the Spanish PETHEMA Group and the Spanish Society of Hematology
Genes, Chromosomes and Cancer, ISSN 1045-2257, 11/2017, Volume 56, Issue 11, pp. 810 - 820
The outcome of relapsed adult acute lymphoblastic leukemia (ALL) remains dismal despite new therapeutic approaches. Previous studies analyzing relapse samples... 
ONCOLOGY | GENETICS & HEREDITY | GENOMIC ANALYSIS | CLONAL EVOLUTION | PROGNOSTIC-SIGNIFICANCE | DRUG-RESISTANCE | MUTATIONS | COHESIN COMPLEX | CHILDHOOD | EXPRESSION | HUMAN CANCER | GENETIC ALTERATIONS | Gene Duplication | Recurrence | Proto-Oncogene Proteins c-ets - genetics | Humans | Middle Aged | PAX5 Transcription Factor - genetics | Leukemia, B-Cell - pathology | Repressor Proteins - genetics | Male | Histone Demethylases - genetics | Tumor Suppressor Protein p53 - genetics | DNA Copy Number Variations | Ikaros Transcription Factor - genetics | Antigens, Nuclear - genetics | Cyclin-Dependent Kinase Inhibitor p18 - genetics | Leukemia, B-Cell - genetics | Cyclin-Dependent Kinase Inhibitor p15 - genetics | Adult | Female | Ataxia Telangiectasia Mutated Proteins - genetics | Nuclear Proteins - genetics | Medical research | Analysis | Stem cells | Medicine, Experimental | Development and progression | Acute lymphocytic leukemia | Drug resistance | Tumor proteins | Cell proliferation | Multiplexing | Deregulation | Copy number | Leukemia | p53 Protein | Genes | Homeostasis | Single-nucleotide polymorphism | Pax5 protein | Alterations | Salvage | Pathways | Reproduction (copying) | Peripheral blood | Bone marrow | Evolution | Lesions | Acute lymphatic leukemia | Lymphatic leukemia | Gene expression | Patients | Lymphocytes B | Diagnostic systems
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study
by Juan José Lahuerta and Maria Victoria Mateos and Joaquin Martínez-López and Carlos Grande and Javier de la Rubia and Laura Rosiñol and Anna Sureda and José García-Laraña and Joaquín Díaz-Mediavilla and Miguel T. Hernández-García and Dolores Carrera and Joan Besalduch and Felipe de Arriba and Albert Oriol and Lourdes Escoda and Javier García-Frade and Concepción Rivas-González and Adrían Alegre and Joan Bladé and Jesús F. San Miguel and Grupo Español de MM and Programa para el Estudio de la Terapéutica en Hemopatía Maligna Cooperative Study Groups and for the GEM (Grupo Espanol de MM) and PETHEMA (Programa para el Estudio de la Terapeutica en Hemopatia Maligna) Cooperative Study Groups
Haematologica, ISSN 0390-6078, 11/2010, Volume 95, Issue 11, pp. 1913 - 1920
The aim of this study was to compare the long-term safety and efficacy of oral busulfan 12 mg/kg plus melphalan 140 mg/m(2) and melphalan 200 mg/m(2) as... 
Oral busulfan | Melphalan | Multiple myeloma | Conditioning regimens | Progression-free survival | Survival | Autologous stem cell transplantation | Busulfan - adverse effects | Follow-Up Studies | Myeloablative Agonists - adverse effects | Multiple Myeloma - mortality | Humans | Male | Transplantation, Autologous | Busulfan - administration & dosage | Stem Cell Transplantation | Melphalan - administration & dosage | Multiple Myeloma - therapy | Melphalan - adverse effects | Aged, 80 and over | Myeloablative Agonists - administration & dosage | Female | Aged | Retrospective Studies | Transplantation Conditioning | Index Medicus | multiple myeloma | melphalan | progression-free survival | oral busulfan | autologous stem cell transplantation | survival | Original | conditioning regimens
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial
by Ribera, Josep-Maria and Ribera, Josep-Maria and Oriol, Albert and Oriol, Albert and Morgades, Mireia and Morgades, Mireia and Montesinos, Pau and Montesinos, Pau and Sarrà, Josep and Sarrà, Josep and González-Campos, José and González-Campos, José and Brunet, Salut and Brunet, Salut and Tormo, Mar and Tormo, Mar and Fernández-Abellán, Pascual and Fernández-Abellán, Pascual and Guàrdia, Ramon and Guàrdia, Ramon and Bernal, María-Teresa and Bernal, María-Teresa and Esteve, Jordi and Esteve, Jordi and Barba, Pere and Barba, Pere and Moreno, María-José and Moreno, María-José and Bermúdez, Arancha and Bermúdez, Arancha and Cladera, Antonia and Cladera, Antonia and Escoda, Lourdes and Escoda, Lourdes and García-Boyero, Raimundo and García-Boyero, Raimundo and Del Potro, Eloy and Del Potro, Eloy and Bergua, Juan and Bergua, Juan and Amigo, María-Luz and Amigo, María-Luz and Grande, Carlos and Grande, Carlos and Rabuñal, María-José and Rabuñal, María-José and Hernández-Rivas, Jesús-María and Hernández-Rivas, Jesús-María and Feliu, Evarist and Feliu, Evarist
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 15, pp. 1595 - 1604
Purpose Minimal residual disease (MRD) is an important prognostic factor in adults with acute lymphoblastic leukemia (ALL) and may be used for treatment... 
B-LINEAGE | THERAPY | PROGNOSTIC-FACTORS | ONCOLOGY | STANDARD-RISK | FREE SURVIVAL | AIEOP-BFM | BLINATUMOMAB | STEM-CELL TRANSPLANTATION | MRD | CHEMOTHERAPY | Multivariate Analysis | Predictive Value of Tests | Age Factors | Humans | Middle Aged | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Patient Selection | Neoplasm, Residual | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Flow Cytometry | Time Factors | Adult | Female | Maintenance Chemotherapy | Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology | Philadelphia Chromosome | Genetic Predisposition to Disease | Consolidation Chemotherapy - mortality | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Logistic Models | Treatment Outcome | Spain | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Disease-Free Survival | Phenotype | Adolescent | Consolidation Chemotherapy - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy
by Pratcorona, Marta and Pratcorona, Marta and Brunet, Salut and Brunet, Salut and Nomdedéu, Josep and Nomdedéu, Josep and Ribera, Josep Maria and Ribera, Josep Maria and Tormo, Mar and Tormo, Mar and Duarte, Rafael and Duarte, Rafael and Escoda, Lourdes and Escoda, Lourdes and Guàrdia, Ramon and Guàrdia, Ramon and Queipo de Llano, M Paz and De Llano, M. Paz Queipo and Salamero, Olga and Salamero, Olga and Bargay, Joan and Bargay, Joan and Pedro, Carmen and Pedro, Carmen and Martí, Josep Maria and Martí, Josep Maria and Torrebadell, Montserrat and Torrebadell, Montserrat and Díaz-Beyá, Marina and Díaz-Beyá, Marina and Camós, Mireia and Camós, Mireia and Colomer, Dolors and Colomer, Dolors and Hoyos, Montserrat and Hoyos, Montserrat and Sierra, Jorge and Sierra, Jorge and Esteve, Jordi and Esteve, Jordi and Grupo Cooperativo Para el Estudio y Tratamiento de las, Cooperativo Para el Estudio y Tratamiento de las and Leucemias Agudas Mieloblásticas, Agudas Mieloblasticas and Grp Cooperativo Estudio and Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas and on behalf of the Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblasticas
Blood, ISSN 0006-4971, 2013, Volume 121, Issue 14, pp. 2734 - 2738
Risk associated to FLT3 internal tandem duplication (FLT3-ITD) in patients with acute myeloid leukemia (AML) may depend on mutational burden and its... 
GENE-MUTATIONS | AML | INTERNAL TANDEM DUPLICATION | ADULT PATIENTS | PROGNOSTIC IMPACT | ACUTE MYELOGENOUS LEUKEMIA | NORMAL CYTOGENETICS | DNMT3A MUTATIONS | LEVEL | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Gene Duplication | Prognosis | Humans | Middle Aged | Risk Factors | Hematopoietic Stem Cell Transplantation | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Secondary Prevention | Tandem Repeat Sequences | Remission Induction | Leukemia, Myeloid, Acute - mortality | fms-Like Tyrosine Kinase 3 - genetics | Disease-Free Survival | Alleles | Adult | Female | Nuclear Proteins - genetics | Leukemia, Myeloid, Acute - therapy | Leukemia, Myeloid, Acute - genetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma
by Espinet, Blanca and Salaverria, Itziar and Beà, Sílvia and Ruiz-Xivillé, Neus and Balagué, Olga and Salido, Marta and Costa, Dolors and Carreras, Joaquim and Rodríguez-Vicente, Ana Eugenia and García, Juan Lús and Hernández-Rivas, Jesús Maŕa and Calasanz, María José and Siebert, Reiner and Ferrer, Ana and Salar, Antonio and Carrió, Ana and Polo, Natividad and García-Marco, José Antonio and Domingo, Alicia and González-Barca, Eva and Romagosa, Vicenç and Marugán, Isabel and López-Guillermo, Armando and Millá, Fuensanta and Mate, José Luís and Luño, Elisa and Sanzo, Carmen and Collado, Rosa and Oliver, Isabel and Monzó, Sebastià and Palacín, Antonio and González, Teresa and Sant, Francesc and Salinas, Ramon and Ardanaz, María Teresa and Font, Llorenç and Escoda, Lourdes and Florensa, Lourdes and Serrano, Sergi and Campo, Elias and Solé, Francesc
Genes Chromosomes and Cancer, ISSN 1045-2257, 2010, Volume 49, Issue 5, pp. 439 - 451
Mantle cell lymphoma (MCL) is a mature B-cell neoplasm with an aggressive behavior, characterized by the t(11;14)(q13;q32). Several secondary genetic... 
TRANSLOCATION | GENE | ONCOLOGY | CYCLIN D1 | DNA | REGIONS | GENETICS & HEREDITY | PROLIFERATION | COMPARATIVE GENOMIC HYBRIDIZATION | HOMOZYGOUS DELETIONS | HISTOPATHOLOGY | CHROMOSOMAL IMBALANCES | Immunohistochemistry | Prognosis | Humans | Middle Aged | Kaplan-Meier Estimate | Lymphoma, Mantle-Cell - pathology | Proportional Hazards Models | Male | Chi-Square Distribution | Lymphoma, Mantle-Cell - diagnosis | Cyclin D1 - genetics | Gene Rearrangement | Chromosome Aberrations | Aged, 80 and over | Adult | Female | Aged | Cytogenetic Analysis | Cell Growth Processes - genetics | Lymphoma, Mantle-Cell - genetics | Cohort Studies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial
by Magnano, Laura and Montoto, Silvia and González-Barca, Eva and Briones, Javier and Sancho, Juan Manuel and Muntañola, Ana and Salar, Antonio and Besalduch, Joan and Escoda, Lourdes and Moreno, Carol and Domingo-Domenech, Eva and Estany, Cristina and Oriol, Albert and Altés, Albert and Pedro, Carmen and Gardella, Santiago and Asensio, Antoni and Vivancos, Pilar and Fernández de Sevilla, Alberto and Ribera, Josep María and Colomer, Dolors and Campo, Elias and López-Guillermo, Armando
Annals of Hematology, ISSN 0939-5555, 4/2017, Volume 96, Issue 4, pp. 639 - 646
Fludarabine combinations are very affective in follicular lymphoma (FL) with high rates of complete response and prolonged survival. However, late toxicities... 
Medicine & Public Health | Hematology | Outcome | Follicular lymphoma | FCM regimen | Oncology | Safety | Secondary neoplasia | SECONDARY MALIGNANCIES | LOW-GRADE LYMPHOMA | PLUS CYCLOPHOSPHAMIDE | INDOLENT LYMPHOMA | CHRONIC LYMPHOCYTIC-LEUKEMIA | NON-HODGKINS-LYMPHOMA | COMBINATION CHEMOTHERAPY | MOLECULAR RESPONSE | HEMATOLOGY | MINIMAL RESIDUAL DISEASE | HISTOLOGICAL TRANSFORMATION | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Lymphoma, Follicular - drug therapy | Survival Rate - trends | Follow-Up Studies | Mitoxantrone - administration & dosage | Humans | Middle Aged | Vidarabine - adverse effects | Lymphoma, Follicular - diagnosis | Lymphoma, Follicular - mortality | Male | Treatment Outcome | Vidarabine - analogs & derivatives | Cyclophosphamide - adverse effects | Time Factors | Adult | Female | Aged | Vidarabine - administration & dosage | Mitoxantrone - adverse effects | Cyclophosphamide | Patient outcomes | Analysis | Leukemia | Clinical trials | Lymphomas | Product development | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Sensibility and taste alterations after impacted lower third molar extractions. A prospective cohort study
by Ridaura-Ruiz, Lourdes and Figueiredo, Rui and Valmaseda-Castellón, Eduard and Berini-Aytés, Leonardo and Gay-Escoda, Cosme
Medicina Oral, Patologia Oral y Cirugia Bucal, ISSN 1698-4447, 09/2012, Volume 17, Issue 5, pp. e759 - e764
Objectives: To determine the incidence, severity and duration of lingual tactile and gustatory function impairments after lower third molar removal. Study... 
Nerve injury | Lingual nerve | Paresthesia | Third molar | Surgical extraction | surgical extraction | NERVE INJURIES | INFERIOR ALVEOLAR | third molar | DAMAGE | RECOVERY | paresthesia | REMOVAL | DENTISTRY, ORAL SURGERY & MEDICINE | nerve injury | GUSTATORY FUNCTION | FREQUENCY | Prospective Studies | Humans | Male | Molar, Third - surgery | Taste Disorders - etiology | Tooth Extraction - adverse effects | Tongue Diseases - etiology | Hypesthesia - etiology | Adult | Female | Surveys and Questionnaires | Tooth, Impacted - surgery | Cohort Studies | Extracció dental | Wisdom tooth | Queixal del seny | Teeth extraction | Peripheral neuropathies | Neuropaties perifèriques | Oral Surgery | Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights